Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Profit After Tax (2018 - 2025)

Serina Therapeutics (SER) has disclosed Profit After Tax for 8 consecutive years, with -$3.3 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 24.2% to -$3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.2 million through Dec 2025, down 72.89% year-over-year, with the annual reading at -$19.2 million for FY2025, 72.17% down from the prior year.
  • Profit After Tax hit -$3.3 million in Q4 2025 for Serina Therapeutics, up from -$4.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $5.2 million in Q2 2024 to a low of -$15.0 million in Q1 2024.
  • Historically, Profit After Tax has averaged -$2.0 million across 5 years, with a median of -$2.3 million in 2021.
  • Biggest five-year swings in Profit After Tax: crashed 270800.0% in 2022 and later surged 540.72% in 2024.
  • Year by year, Profit After Tax stood at -$2.2 million in 2021, then decreased by 27.35% to -$2.8 million in 2022, then surged by 138.07% to $1.1 million in 2023, then tumbled by 355.57% to -$2.7 million in 2024, then fell by 24.2% to -$3.3 million in 2025.
  • Business Quant data shows Profit After Tax for SER at -$3.3 million in Q4 2025, -$4.6 million in Q3 2025, and -$6.5 million in Q2 2025.